Company Filing History:
8 out of 44 
7 out of 41 
3 out of 21 
Years Active: 2007-2015
Title: Désiré Collen: A Pioneer in Treating Neuron Disorders and Pathological Angiogenesis
Introduction:
Désiré Collen, hailing from Winksele, Belgium, is a renowned figure in the field of biotechnology and medical research. With a remarkable track record of innovation, Collen has made significant contributions to the treatment of neuron disorders and pathological angiogenesis. This article delves into his latest patents, career highlights, and notable collaborations.
Latest Patents:
Collen's latest patents demonstrate his commitment to advancing medical treatments. His first patent, "Anti-angiogenic therapy," introduces novel monoclonal antibodies directed to PlGF (Placental Growth Factor) and its derivatives. These antibodies have shown promise in treating and preventing pathological angiogenesis, offering new possibilities for combating diseases such as cancer.
His second patent, "Use of VEGF and homologues to treat neuron disorders," explores the connection between neurological dysfunction and neuron disorders. Collen's research identifies the role of vascular endothelial growth factor (VEGF) and its homologues in motor neuron disorders, particularly amyotrophic lateral sclerosis (ALS). His invention also involves the usage of VEGF isoforms for neuron disorder treatment and the diagnosis of related disorders based on polymorphisms in the VEGF promoter.
Career Highlights:
Throughout his illustrious career, Collen has made significant contributions to the field of biotechnology. He has held key positions at prestigious organizations such as the Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw and Life Sciences Research Partners Vzw. Collen's work within these organizations has not only elevated his own profile but also brought groundbreaking advancements in medical research to the forefront.
Collaborations:
Collen's research efforts have been greatly enhanced by collaborations with esteemed colleagues. Notably, his partnership with Peter Carmeliet and Bert Oosthuyse has allowed for the exchange of ideas, resources, and expertise in developing innovative treatments for neuron disorders and pathological angiogenesis. These collaborations have nurtured an environment of scientific excellence, propelling Collen's work to new heights.
Conclusion:
Désiré Collen exemplifies the ingenuity and dedication of a true innovator in the biotechnology and medical research fields. His patents on anti-angiogenic therapy and the usage of VEGF for neuron disorders have opened new doors for treatments and diagnostics. Collen's career highlights and collaborations underline his commitment to pushing boundaries and advancing medical science for the betterment of human health. As we wait in anticipation for his future innovations, Collen's research continues to inspire and pave the way for further breakthroughs in the field.